Key Takeaways
- Reset complete, guidance issued: FY24 was the "best year" for revenues and absolute EBITDA, and the company says it completed its reset ahead of schedule. FY25 guidance calls for 12–15% overall growth, with the bulk weighted to H2.
- US business anchors the story: The niche limited-competition strategy is on track toward a $400 million aspirational target in 2–3 years, with FY25 guided at $285–300 million. A weak flu season was offset by the Generic Suprep launch, which captured pole position market share.
- OneSource reaches breakeven, demerger advances: OneSource (formerly Stelis) reported its first-ever breakeven quarter and received SEBI approval for its demerger scheme. FY25 is guided for only marginal growth as major product approvals arrive late in the year.
- Margins have room to run: Gross margins held at 60.7% and are seen as sustainable within plus/minus 2%. Management sees 200–250 bps of further margin expansion from cost improvements and network optimization, targeting a return to the 21%+ EBITDA peak in 12–18 months.
- What to watch next quarter: Whether the H2-weighted growth materialises on schedule, the pace of debt reduction toward the sub-2x target, and the NCLT filing timeline for the OneSource demerger.
US Business: The $400 Million Engine
- Niche strategy, calibrated execution: The US business is built on limited-competition products where the company targets a 25–30% market share in three-to-four-player markets. When pricing is heavily challenged, the company exits the product entirely rather than chase volume.
- Suprep win offset flu weakness: A very weak flu season in Q3 and Q4 was offset by the Generic Suprep launch, where the company won contracts to achieve pole position market share.
- Service as a moat: The company maintained a 99% service level with failure-to-supply costs at sub-$200,000 on a $250 million business, described as gold standards in the industry.
- Endo portfolio turns profitable: The endo P&L is now significantly profitable on a standalone basis after two difficult years, with the number-one selling product being an endo product. One more endo product launches this year with an exit run rate similar to the top seller.
- Beyond $400 million requires differentiation: The current niche limited-competition strategy caps growth at $400 million. To go beyond, the company needs platform technology or US manufacturing capabilities (controlled substances, laser space, complex devices, liquids) that require capabilities beyond what exists in India, currently being invested in globally with partners or organically.
- No incremental investment needed for $400 million: All products are already approved and R&D for that run rate is nearly complete. Investment is now directed at the "400 beyond" story.
Arun Kumar: "The current strategy of niche limited competition kind of limits our growth to $400 million. That's our aspirational growth. We are now very confident we can achieve that."
OneSource (Stelis) & the Demerger
- Breakeven milestone achieved: OneSource reported its first-ever breakeven quarter, as management had guided.
- Demerger approvals secured: SEBI approval was received late on the night before the call, the last step prior to the NCLT court process. Filing is expected to commence in the next couple of weeks, with the court process typically taking 3–4 quarters and roughly 60 days thereafter for stock exchange listing.
- Drug substance capability winning business: The drug substance capability established about six months ago won its first major NCE contract. New customers are being added every month across platforms, with wins in both GLP and non-GLP programs.
- FY25: a holding year for approvals: FY25 is guided for very marginal growth because more product approvals in both the drug substance and drug product divisions are expected only toward the last quarter of FY25.
- Capacity expansion underway: A capacity expansion will complete in FY26 to take drug-device combination capacity from 4 crore to 20 crore units.
- Long-term target intact: The $400 million revenue target, set for three years from the time of OneSource's listing, remains very much on track.
Growth Levers Beyond the US
- Other Regulated Markets (ORM) growing at 20%: Growth appears slower because the business is largely B2B: when licensing products to global players, they launch in 15–20 countries simultaneously, stretching the launch period. Numbers are expected to change significantly upwards in H2.
- GLP-1 commercial supplies commencing: First commercial supplies of GLP begin in FY25, with the Liraglutide launch expected in H2 of FY25.
- Institutional segment set for a rebound: The segment was impacted in FY24 by low tender allocation, but significantly higher allocation is expected on the program for the next two years, with more upticks in H2.
- Nasal spray and 505(b)(2) pipeline building: A partnership for nasal sprays in controlled substances was announced, with the first filing expected this financial year. The first 505(b)(2) filing is expected around the middle of the next financial year.
- Orbicular partnership progressing: The first filing is expected this year, with the entire platform program to be completed during the next 12 months and approvals thereafter. There is significant interest in exclusive controlled-substance programs.
- Biosecurity Act tailwind emerging: The Act has been diluted significantly with a 7–8 year window for companies dependent on China, but the company is seeing a significant amount of new RFPs for biologics as the China Plus One dynamic plays through.
Arun Kumar: "Clearly, the Biosecurity Act has been diluted quite significantly and there is a 7 to 8 year window for companies dependent on China to find solutions or alternative solutions. But we are seeing significant amount of new RFPs for biologics. And I think the China Plus One on the biologics is playing through."
Margins & Cost Structure
- Gross margins locked in a tight band: Q4 gross margins of 60.7% are sustainable within plus/minus 2%, having been achieved for four quarters or more.
- Overhead control has been consistent: The company has done a good job controlling overhead costs and optimizing the cost structure over several quarters.
- 200–250 bps of further expansion identified: Further margin expansion is expected through cost improvements and completion of network optimization, targeting a return to the 21.5% peak EBITDA percentage.
- Soft gelatine a near-term drag: The soft gelatine business will be soft in terms of EBITDA because two very big approvals came in FY24, with new product approvals not expected until FY26. It will still deliver small growth over the USD 2 crore EBITDA base.
- Red Sea crisis behind: Shipping premiums have dropped dramatically; for now it is business as usual, though vigilance is needed.
Arun Kumar: "We probably have about 200 to 250 basis points of margin expansion through cost improvements and completion of network optimization. And that is why we said our dream goal is to get to our 21.5% peak EBITDA percentage-wise. And we think we can do that in the next 12 to 16 to 18 months."
Balance Sheet & Capital Allocation
- Debt reduction ahead of schedule: The company achieved its debt outlook far ahead of the scheduled 3x debt-to-EBITDA ratio.
- FY25 debt target: Reduce debt by an additional INR 500 crores after spending almost INR 200 crores in capex, with no intention to achieve this through new borrowings. The FY25 debt-to-EBITDA target is under 2x.
- Long-term goal: debt-free in 3–4 years: Management aims to be debt-free in three to four years from now.
- Free cash flow conversion strong: The company generated very significant free cash flow of almost INR 700 crores, with a 95% EBITDA-to-cash conversion ratio.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall revenue growth | 12% to 15% growth, bulk in H2 | FY25 |
| EBITDA (company level) | INR 950 crores to INR 1,000 crores | FY25 |
| EBITDA (retained business) | INR 750 crores to INR 800 crores | FY25 |
| US business revenue | $285 million to $300 million | FY25 |
| US business long-term target | $400 million size | Next 2 to 3 years |
| Debt reduction | Reduce debt by INR 500 crores after INR 200 crores capex | FY25 |
| Debt-to-EBITDA ratio | Under 2x | FY25 |
| Debt-free | Zero debt | 3 to 4 years |
| EBITDA margin | Return to 21%+ (21.5% peak) | Next 12 to 18 months |
| OneSource profitability | Profitable division | FY25 |
| OneSource NCLT filing | Commence filing | Next couple of weeks |
| OneSource revenue target | $400 million | 3 years from listing |
| OneSource capacity expansion | 4 crore to 20 crore drug-device combination units | FY26 |
| Nasal spray first filing | First filing | FY25 |
| 505(b)(2) first filing | First filing | Middle of next financial year |
| GLP-1 commercial supplies | First commercial supplies commence | FY25 |
| Liraglutide launch | Launch | H2 FY25 |
| Orbicular platform completion | Entire platform program completed | Next 12 months |
| Demerger completion | Court process (3–4 quarters) plus ~60 days for listing | Filing this quarter |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | Shade under $500 million for FY24 |
| Gross margin | 60.7% in Q4, sustainable plus/minus 2%; FY24 consistent between 59% and 60% |
| EBITDA margin | 19.3%, moving up from 16% |
| Adjusted PAT | Around INR200 crores for former business |
| US business revenue | $250 million at the higher end of the outlook, bang on target |
| US business FY25 revenue guidance | $285 million to $300 million |
| Other regulated markets growth | 19%, almost 20% |
| Access and growth markets growth | Almost about 25% |
| Debt-to-EBITDA ratio | 2.72x |
| Free cash flow | Almost INR700 crores, almost 95% of EBITDA-to-cash conversion ratio |
| ROCE exit run rate | 15% |
| Gross block to asset turnover | Almost 5x |
| US business failure to supply | Sub-$200,000 for a $250 million business |
| Drug device combination capacity | 4 crore units, expanding to 20 crore units in FY26 |
| Stelis (OneSource) profitability | First-ever quarter with a breakeven |